OXFORD-ASTRAZENECA COVID VACCINE

Reactive Axillary Lymphadenopathy for SARS-CoV-2 Vaccines in the Asian Taiwanese Population

Chimei Medical CentervaccineActive

30/ 100

Provisional rating · Methodology v0.2

Rating breakdown

2 Active assets in the Reactive Axillary Lymphadenopathy for SARS-CoV-2 Vaccines in the Asian Taiwanese Population cohort.

Asset / Sponsor	Phase	Rating
LEUPROLIDE University of California, San Francisco	Phase 2	CCC
Enzalutamide University of California, San Francisco	Phase 2	CCC
Indocyanine Green Oxford University Hospitals NHS Trust	Phase 1/2	CCC
MODERNA COVID-19 VACCINE RNA Chimei Medical Center		D
Tozinameran Chimei Medical Center		D
Carbon Nanoparticle Suspension The First Affiliated Hospital with Nanjing Medical University	N/A	NR

Order a full diligence report on this asset.

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.